Business
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day
About this update from Immunitybio, Inc.
[{"type":"text","content":" CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company’s business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company’s research programs.\n\nThe discussions will include clinical and regulatory updates on the company’s bladder cancer program, regenerative medicine advanced therapy (RMAT) designations, including results on non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer trials, as well as lymphopenia rescue data related to these trials (Cancer BioShield).\n\nIn addition, updates will be provided on the natural killer (NK) cell therapy program, the Lynch syndrome accrual and fireside chats on virally induced cancers, including discussions on Long-COVID.\n\nThe key opinion leaders participating in the fireside chats with ImmunityBio leadership include:\n\n\nDr. Christopher Pieczonka – Chief Executive Officer, Associated Medical Professionals of New York & Corporate Director of Clinical Research of US Urology Partners\n\n\nDr. Steven Finkelstein – National Director of Radiation Oncology, US Urology Partners. Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research\n\n\nDr. Mark Lanasa – Senior Vice President, Chief Medical Officer, Solid Tumors, BeiGene\n\n\nDr. Jennifer Buell – President & Chief Executive Officer, MiNK Therapeutics\n\n\nDr. Krishnansu Tewari – Gynecologic Oncology, Obstetrics & Gynecology at UC Irvine Health\n\n\nDr. David Kerr - Professor of Cancer Medicine Genetics and Genomics, University of Oxford\n\n\nDr. Timothy Heinrich – Professor, School of Medicine UC San Francisco\n\n\nDr. Carlos Cardo-Cardon – Chairman for the Mount Sinai Health System Dept. of Pathology\n\n\nKey timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials.\n\nThe program will feature a presentation by ImmunityBio Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, outlining the fundamental science underpinning the compa...